arrow
T

Takayuki Ueno

breast oncology center
H指数:42
被引数:7,252

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-world event-free survival with neoadjuvant pembrolizumab plus chemotherapy and adjuvant pembrolizumab in early-stage triple-negative and estrogen receptor-low, HER2-negative breast cancer

早期三阴性及雌激素受体低表达、HER2阴性乳腺癌患者接受新辅助 pembrolizumab 联合化疗及辅助 pembrolizumab 治疗的真实世界无事件生存情况

2026-10-060
OAAI
Real-world outcomes of datopotamab deruxtecan after trastuzumab deruxtecan in hormone receptor–positive, HER2-negative metastatic breast cancer

曲拉妥单抗德鲁克替康后,在激素受体阳性、HER2阴性转移性乳腺癌中的真实世界结局

2026-09-020
OAAI
Cytotoxic immune activity reflects a coordinated immune microenvironment and is associated with response to total neoadjuvant therapy in rectal cancer

细胞毒性免疫活性反映协调的免疫微环境,并与直肠癌中总新辅助治疗的应答相关

2026-08-180
PRE
Super homotypic targeting by surface engineering of extracellular vesicles

通过细胞外囊泡的表面工程实现超同型靶向

2026-07-220
OAAI
Health-related quality of life with pertuzumab retreatment: Secondary analysis of the PRECIOUS trial

接受帕妥珠单抗再治疗患者的生活质量:PRECIOUS试验的二次分析

Breast
IF7.9
2026-05-230
OAAI
Prevalence and clinical significance of germline pathogenic variants identified by multigene panel testing in high-risk Japanese patients with breast cancer

通过多基因面板检测在高风险日本乳腺癌患者中发现的生殖系致病性变异的流行病学和临床意义

2026-05-130
PREAI
Axillary adipose tissue–derived lymphatic endothelial cells exhibit distinct transcriptomic signatures reflecting lymphatic invasion status in breast cancer

腋窝脂肪组织来源的淋巴管内皮细胞表现出反映乳腺癌淋巴管侵犯状态的独特转录组特征。

2026-04-080
OAAI
ASO Visual Abstract: Feasibility of Omitting Axillary Dissection After Repeat Sentinel Lymph Node Biopsy for Ipsilateral Breast Tumor Recurrence: A Single-Center Retrospective Study

ASO视觉摘要:重复前哨淋巴结活检后省略腋窝清扫在患侧乳腺癌复发中的可行性:一项单中心回顾性研究

2026-02-060
PRE
Characterizing heterogeneous cis-regulatory elements in gene regulatory programs associated with breast cancer

表征与乳腺癌相关的基因调控程序中的异质性顺式调控元件

2025-11-270
OAAI
Adjuvant S-1 plus endocrine therapy for ER-positive, HER2-negative, primary breast cancer: post-POTENT trial prognostic survey

ER阳性、HER2阴性原发性乳腺癌的辅助S-1联合内分泌治疗:POTENT试验后的预后调查

2025-10-240
OA
Efficacy and feasibility of neoadjuvant pembrolizumab plus chemotherapy for early-stage triple-negative and estrogen receptor low, HER2-negative breast cancer: a Japanese single-institution real-world study

新辅助帕博利珠单抗联合化疗治疗早期三阴性和雌激素受体低下的HER2-negative乳腺癌的疗效和可行性: 一项日本单机构真实世界研究

2024-12-070
PRE